Rapamycin in Relapsed Acute Lymphoblastic Leukemia
- Participants will be randomized into two groups; one group will receive corticosteroid
alone, and the other group will receive rapamycin and corticosteroid.
- The length of treatment will be 5 days, during which time we will collect blood samples
to measure the biologic effects of these drugs. Because these drugs will be given for
a short period of time only, this study is not designed to treat or cure the
participants leukemia. After the 5-day period, participants may resume other
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label
Compare changes in gene expression signatures in steroid alone versus steroid plus rapamycin treated patients.
Lewis Silverman, MD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|